COPENHAGEN, Denmark and SEATTLE, Washington, June 22, 2011 /PRNewswire/ --
CMC Biologics today announced that it is in the final stages of expanding its stainless steel biopharmaceutical production facility at its Bothell campus and it has rebranded its corporate identity with an exciting new logo and a compelling tagline. These recent changes are part of the continued growth of the Company.
The Company is completing the expansion of its state-of-the-art stainless steel biopharmaceutical manufacturing facility, known as PF2, to increase capacity and support commercial manufacturing with the addition of a 3,000 liter bioreactor train. The modification of PF2 is part of a staged major expansion plan that started with the construction of a multipurpose single-use facility (PF1), completed in 2010, and is expected to include the build-out of a facility to house two 5,000 liter commercial-ready manufacturing lines.
"We measure our success by the results we deliver to our customers," said Gustavo F. Mahler, Ph.D., Global Chief Operations Officer of CMC Biologics. "The expansion of PF2 will add significant production capacity to CMC Biologics' existing facilities to accommodate growing demand for cGMP manufacture of biopharmaceuticals."
"The rebranding, which coincides with the Company's tenth anniversary, isn't just about a new logo. It's about our reputation and image in the market," noted Claes Glassell, CEO of CMC Biologics. "The new tagline 'Right. On Time.' conveys our commitment to our customers."
About CMC Biologics
CMC Biologics (http://www.cmcbio.com) is a dedicated contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes.
SOURCE CMC Biologics